|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Schizophrenia | |||||
| Psychotic Disorders | |||||
| 2 | More general conditions related to this trial | ||||
| Mental Disorders | |||||
| Schizophrenia and Disorders with Psychotic Features | |||||
| 3 | Interventions listed in this trial | ||||
| Placebo | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| 3-(2,4-dimethoxybenzylidene)anabaseine | |||||
| 5 | More general drug interventions related to this trial | ||||
| Cholinergic Agents | |||||
| Cholinergic Agonists | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Neurotransmitter Agents | |||||
| Nicotinic Agonists | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| 6 | Sponsors listed in this trial | ||||
| National Institute of Mental Health (NIMH) | |||||